SAN DIEGO, June 30, 2021 – Coastar Therapeutics Inc., an emerging biotech company focused on biological payload delivery technology for cancer immunotherapy and gene therapy, today announced that it has successfully closed seed round funding.

“This is a historical moment for Coastar, and we are truly grateful to our investors for their confidence in us,” said Eddie Y. Chung, Founder and CEO of Coastar Therapeutics.“ With the newly raised funding, we are ready to accelerate the research and development programs in cell membrane coating technology for oncolytic virotherapy and gene therapy.”

“We are excited to embark on the journey of discovery,” said Han L. Lim, Co-founder and Chief Science Officer of Coastar Therapeutics. “The funding enables to further develop our technology and generate important data that will lead to IND-enabling studies.”

Coastar Therapeutics has developed an innovative cell membrane coating technology platform that enables a wide range of biological payloads to avoid immune clearance and be successfully delivered to disease sites. The technology will lead to increased efficacy, reduced toxicity, lower cost and more applications in cancers and other diseases.

ABOUT COASTAR THERAPEUTICS

Coastar Therapeutics Inc., is a San Diego based company developing biological payload delivery technologies for cancer and gene therapies. The company’s proprietary ENHEnS^TM technology can coat cell membranes on biological payloads to help them evade recognition and clearance by the immune system and be successfully delivered to tumor or other disease sites (YouTube link: https://youtu.be/4BMdkyJ09nM). The company is developing coatings for oncolytic viruses in cancer immunotherapy as well as for AAV in gene therapy.